Exploring the use of tyrosine kinase inhibitors (TKIs) in the management of HER2positive metastatic breast cancer post trastuzumab emtansine (TDM1) therapy failure: Insights from a real-world study

被引：0
|
作者：
Yin, Yongmei
Sun, Chunxiao
Hua, Yijia
Jin, Nan
Li, Wei
Huang, Xiang
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-04-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-04-06
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tyrosine kinase inhibitors (TKIs) in trastuzumab emtansine (T-DM1) resistant HER2positive metastatic breast cancer: A real-world study.
    Yin, Yongmei
    Sun, Chunxiao
    Hua, Yijia
    Jiang, Mengping
    Yang, Fan
    Wu, Xinyu
    Zeng, Tianyu
    Bao, Shengnan
    Liang, Yan
    Huang, Xiang
    Li, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Treatment with tyrosine kinase inhibitors (TKIs) in HER2-positive metastatic breast cancer after trastuzumab emtansine (T-DM1) failure: A real-world study
    Yin, Yongmei
    Li, Wei
    Huang, Xiang
    Sun, Chunxiao
    Hua, Yijia
    Jin, Nan
    Wu, Xinyu
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Tyrosine kinase inhibitors (TKIs) in HER2-positive metastatic breast cancer after trastuzumab emtansine (T-DM1) failure: A multicenter real-world study
    Sun, C.
    Yin, Y.
    Li, W.
    Huang, X.
    Hua, Y.
    Jin, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S368 - S369
  • [4] Tyrosine kinase inhibitors in HER2-positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real-world study
    Sun, Chunxiao
    Hua, Yijia
    Jin, Nan
    Wang, Xiaojia
    Huang, Jian
    Wu, Xinyu
    Zeng, Tianyu
    Yan, Xueqi
    Yang, Fan
    Liang, Yan
    Huang, Xiang
    Li, Wei
    Yin, Yongmei
    MEDCOMM, 2024, 5 (07):
  • [5] Treatment with tyrosine kinase inhibitors (TKIs) based therapy in trastuzumab emtansine (T-DM1) resistant HER2-positive metastatic breast cancer: A real-world study
    Hua, Y.
    Sun, C.
    Jiang, M.
    Yang, F.
    Wang, X.
    Bao, S.
    Wu, X.
    Huang, X.
    Li, W.
    Yin, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S491 - S491
  • [6] The effectiveness of trastuzumab emtansine (TDM1) in metastatic breast cancer based on the duration of response to adjuvant HER2-targeted therapy
    Milovic-Kovacevic, M.
    Novakovic, T.
    Bobic, S.
    Pavlovic, L.
    Karaferic, A.
    Matovic, M.
    BREAST, 2025, 80
  • [7] Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
    Bahceci, Aykut
    Paydas, Semra
    Ak, Naziye
    Ferhatoglu, Ferhat
    Saip, Pinar Mualla
    Seydaoglu, Gulsah
    Bilici, Mehmet
    Simsek, Melih
    Tekin, Salim Basol
    Calikusu, Zuleyha
    Yavuz, Sinan
    Sahin, Ahmet Bilgehan
    Cubukcu, Erdem
    Evrensel, Turkkan
    Degirmencioglu, Serkan
    Demiray, Atike Gokcen
    Yumuk, Perran Fulden
    Alan, Ozkan
    Cikman, Duygu Ilke
    Demirelli, Fuat Hulusi
    Kostek, Osman
    Gokyer, Ali
    Dogan, Mutlu
    Bal, Oznur
    Cakar, Burcu
    Gokmen, Erhan
    Yamac, Deniz
    Korkmaz, Taner
    Aliyev, Altay
    Keskin, Ozge
    Urvay, Semiha
    Buyuksimsek, Mahmut
    Karadeniz, Cemile
    Yildiz, Birol
    Cinkir, Havva Yesil
    Demir, Hacer
    Beypinar, Ismail
    Karacin, Cengiz
    Eser, Kadir
    Baykara, Meltem
    Kilickap, Saadettin
    Okutur, Kerem
    Bulut, Gulcan
    Alkan, Ali
    Arpaci, Erkan
    Pilanci, Kezban Nur
    Demir, Atakan
    Isik, Deniz
    Yildirim, Nilgun
    CANCER INVESTIGATION, 2021, 39 (6-7) : 473 - 481
  • [8] A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
    Vici, Patrizia
    Pizzuti, Laura
    Michelotti, Andrea
    Sperduti, Isabella
    Natoli, Clara
    Mentuccia, Lucia
    Di Lauro, Luigi
    Sergi, Domenico
    Marchetti, Paolo
    Santini, Daniele
    Magnolfi, Emanuela
    Iezzi, Laura
    Moscetti, Luca
    Fabbri, Agnese
    Cassano, Alessandra
    Grassadonia, Antonino
    Omarini, Claudia
    Piacentini, Federico
    Botticelli, Andrea
    Bertolini, Ilaria
    Scinto, Angelo Fedele
    Zampa, Germano
    Mauri, Maria
    D'Onofrio, Loretta
    Sini, Valentina
    Barba, Maddalena
    Maugeri-Sacca, Marcello
    Rossi, Ernesto
    Landucci, Elisabetta
    Tomao, Silverio
    Alberti, Antonio Maria
    Giotta, Francesco
    Ficorella, Corrado
    Adamo, Vincenzo
    Russo, Antonio
    Lorusso, Vito
    Cannita, Katia
    Barni, Sandro
    Laudadio, Lucio
    Greco, Filippo
    Garrone, Ornella
    Della Giulia, Marina
    Marolla, Paolo
    Sanguineti, Giuseppe
    Di Cocco, Barbara
    Ciliberto, Gennaro
    De Maria, Ruggero
    Gamucci, Teresa
    ONCOTARGET, 2017, 8 (34) : 56921 - 56931
  • [9] Trastuzumab emtansine in HER2-positive metastatic breast cancer after pertuzumab and trastuzumab: TDM1RM Study
    Martinez-Garcia, J.
    Puertes Boix, A.
    Sanchez Henarejos, P.
    Jimenez Lucas, M. D.
    Sanchez Saura, A.
    Luengo, M.
    Carrillo Vicente, R.
    Martinez Ortiz, M. J.
    Balsalobre, J.
    de la Morena Barrio, P. D. L. M.
    Garcia Garre, E.
    Garcia, E.
    Marin, G.
    Garcia Torralba, E.
    Ayala de la Pena, F.
    Collado, D.
    Lopez, A.
    Quiros, T.
    Sanchez, D. A.
    Romero, J. L. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S358 - S358
  • [10] Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
    Sanglier, Thibaut
    Shim, Jinjoo
    Lamarre, Neil
    Pena-Murillo, Claudia
    Antao, Vincent
    Montemurro, Filippo
    BREAST, 2023, 69 : 441 - 450
12345